Does TREPROSTINIL Cause Hyperkeratosis? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hyperkeratosis have been filed in association with TREPROSTINIL (TYVASO). This represents 0.0% of all adverse event reports for TREPROSTINIL.
7
Reports of Hyperkeratosis with TREPROSTINIL
0.0%
of all TREPROSTINIL reports
0
Deaths
3
Hospitalizations
How Dangerous Is Hyperkeratosis From TREPROSTINIL?
Of the 7 reports, 3 (42.9%) required hospitalization.
Is Hyperkeratosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does TREPROSTINIL Cause?
Dyspnoea (16,348)
Headache (14,051)
Diarrhoea (11,335)
Nausea (10,320)
Cough (8,945)
Fatigue (7,440)
Dizziness (7,405)
Infusion site pain (5,169)
Vomiting (5,097)
Death (4,764)
What Other Drugs Cause Hyperkeratosis?
CABOZANTINIB S-MALATE (411)
ADALIMUMAB (332)
SUNITINIB MALATE (170)
ETANERCEPT (168)
SORAFENIB (150)
METHOTREXATE (149)
VEMURAFENIB (145)
REGORAFENIB (136)
RIPRETINIB (124)
RITUXIMAB (121)
Which TREPROSTINIL Alternatives Have Lower Hyperkeratosis Risk?
TREPROSTINIL vs TREPROSTINIL DIOLAMINE
TREPROSTINIL vs TRETINOIN
TREPROSTINIL vs TRIAMCINOLONE
TREPROSTINIL vs TRIAMCINOLONE ACETONIDE
TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE